key: cord-0994908-gro6i11f
authors: Pollock, N. R.; Tran, K.; Jacobs, J. R.; Cranston, A. E.; Smith, S.; O'Kane, C. Y.; Roady, T. J.; Moran, A.; Scarry, A.; Carroll, M.; Volinsky, L.; Perez, G.; Patel, P.; Gabriel, S.; Lennon, N. J.; Madoff, L. C.; Brown, C.; Smole, S. C.
title: Performance and Operational Evaluation of the Access Bio CareStart Rapid Antigen Test in a High-throughput Drive-through Community Testing Site in Massachusetts
date: 2021-03-09
journal: nan
DOI: 10.1101/2021.03.07.21253101
sha: 91042b5fcb90cf2afba36b861640d4f6bf5d52fc
doc_id: 994908
cord_uid: gro6i11f

Background: To facilitate deployment of point-of-care testing for SARS-CoV-2, we evaluated the Access Bio CareStart COVID-19 Antigen test in a high-throughput, drive-through, free community testing site using anterior nasal (AN) swab RT-PCR for clinical testing. Methods: Consenting symptomatic and asymptomatic children ([≤]18 years) and adults received dual AN swabs. CareStart testing was performed with temperature/humidity monitoring. All tests had two independent reads to assess inter-operator agreement. Patients with positive CareStart results were called and instructed to isolate pending RT-PCR results. The paired RT-PCR result was the reference for sensitivity and specificity calculations. Results: Of 1603 participants, 1245 adults and 253 children had paired RT-PCR/CareStart results and complete symptom data. 83% of adults and 87% of children were asymptomatic. CareStart sensitivity/specificity were 84.8% (95% confidence interval [CI] 71.1-93.7)/97.2% (92.0-99.4) and 85.7% (42.1-99.6)/89.5% (66.9-98.7) in adults and children, respectively, within 5 days of symptoms. Sensitivity/specificity were 50.0% (41.0-59.0)/99.1% (98.3-99.6) in asymptomatic adults and 51.4% (34.4-68.1)/97.8% (94.5-99.4) in asymptomatic children. Sensitivity in all 234 RT-PCR-positive people was 96.3% with cycle threshold (Ct) [≤]25, 79.6% with Ct [≤]30, and 61.4% with Ct [≤]35. All 21 false positive CareStart tests had faint but normal bands. Inter-operator agreement was 99.5%. Operational challenges included identification of faint test bands and inconsistent swab elution volumes. Conclusions: CareStart had high sensitivity in people with Ct [≤]25 and moderate sensitivity in symptomatic people overall. Specificity was unexpectedly lower in symptomatic versus asymptomatic people. Excellent inter-operator agreement was observed, but operational challenges indicate that operator training is warranted.

in brief, collection involved swabbing both nostrils with each swab and operators alternated 123 which swab was collected first (for RT-PCR vs. CareStart). CareStart swabs were captured in an 124 empty sterile tube and taken to the testing trailer by a designated "runner." Time of sample 125 collection was recorded, and CareStart tests were initiated within an hour of collection. 126 127 Access Bio CareStart COVID-19 Antigen test performance 128

The test was performed by trained operators (Master's or PhD level laboratorians) according to 129 the manufacturer instructions for use (IFU) [12] ; note that testing of individuals with symptoms 130 >5 days or without symptoms is off-label. Details of kit storage, quality control, and testing and 131 were informed that the Ag result was presumptive positive and that they should isolate until they 142 received their confirmatory RT-PCR result in 1-2 days. If the RT-PCR result was negative, they 143 could discontinue isolation. RT-PCR results were provided to the patient by the Lawrence 144

General Hospital's portal or by walk up to a designated location at the Lawrence General 145

Hospital. RT-PCR results were reported to DPH through routine electronic laboratory reporting 146 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 mechanisms and individuals with positive results were referred to local boards of health or the 147 Sensitivity in adults with symptoms ≤5D was 84.8%, similar to that in the CareStart IFU (87.2%) 183 [12] . Sensitivity in children with symptoms ≤5D was 85.7%. Specificity in these symptomatic 184 adults and children were 97.2% and 89.5%, respectively. Relative to symptomatic individuals, 185 sensitivity in asymptomatic adults and children was lower at 50.0% and 51.4%, respectively, 186 while specificity was higher (99.1% and 97.8%, respectively). respectively; no excess mucus was observed. Ninety-nine false negative CareStart results were 195 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint found in 1498 individuals; 5/99 swabs had been minimally bloody and 1/99 had excess mucous. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint distinguishing them from negative results required very close observation and good lighting, 220 particularly due to the blue color of a faint positive band potentially resembling a shadow. A 221 subset of 10 extracted samples with positive CareStart results were retested four hours later (as 222 per the IFU [12], samples can sit for up to 4 hours in extraction buffer before testing) and all 10 223 repeat results were qualitatively the same as the original results. 224 225 Operators noted that the volume of extraction buffer absorbed by the swab head was 226 inconsistent, and that it was sometimes difficult to elute sufficient volume from the head of the 227 swab for testing (a process that requires squeezing the sides of the extraction vial [12] ). This 228 issue required careful observation and, ultimately, experience to overcome. Additionally, 229 operators noted that the polyester swab head did not seem completely stable (occasional apparent 230 unravelling of the head surface, at an anecdotal rate of up to 5/200 tests per day). Coincidentally, 231 the same swab brand was already in use for RT-PCR testing at this site, making it possible to 232 confirm that this "unravelling" at the time of patient swabbing had already been observed over 233 an extended time period with this particular swab. The operators found that a good deal of force 234 was required to fit the caps on the extraction vials, and that the cap did not "click" as per the 235 IFU, leading to concerns about spillage; they also found that peeling the foil off of the extraction 236 vial was difficult and sometimes led to dripping of buffer and slippery gloves. Each skilled 237 laboratorian was able to perform and read ~20 tests per hour; operators felt that throughput was 238 limited by the short read time window (5' The development of Ag RDTs offers the opportunity to dramatically expand COVID-19 testing 243 capacity and also raises critical questions about how these tests could and should be used. Field 244 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint evaluation of an Ag RDT at POC in the settings and populations of intended use can add 245 tremendously to the performance data available in manufacturer package inserts and guide test 246 deployment. Gaps in performance data, particularly test performance in asymptomatic adults 247 and both symptomatic and asymptomatic children, must be filled in order to optimally deploy Ag 248

Prior to this study, only minimal data for performance of the CareStart test in symptomatic 250 individuals was available in the manufacturer's IFU [12] . In order to understand how well the 251 CareStart RDT could perform in both symptomatic and asymptomatic adults and children in a 252 real-world but also best-case testing scenario, we implemented the test at a high-volume 253 community testing site already experienced in collecting AN samples for RT-PCR. Sensitivity in asymptomatic adults and children was substantially lower than that in symptomatic 264 individuals, which may correspond with the broad viral load distribution observed in this 265 population (likely capturing early and late infections given unknown disease onset). Thus, the 266 test does not appear to be optimal for ruling out SARS-CoV-2 infection in asymptomatic adults 267 or children; use in serial testing programs and for testing of contacts of known cases deserves 268 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. Unexpectedly, we found that specificity of the CareStart test was lower in symptomatic people 283 than in asymptomatic people: specificity in adults/children within 5D of symptoms were 284 97.2%/89.5% and in asymptomatic adults/children were 99.1%/97.8%, respectively. This pattern 285 was not observed in our BinaxNOW study (100% specificity in people within 7D of symptoms, 286 and 99.6%/99.0% specificity in asymptomatic adults/children, respectively [6]) nor in the Access 287

Bio prospective AN swab study detailed in the CareStart EUA IFU (100% specificity in 288 symptomatic individuals [12] ). This specificity is also lower than that observed in a number of 289 other field studies of visually-read Ag RDTs, including the BinaxNOW, SD Biosensor SD Q, 290 and Abbott PanBio RDTs (>99% for all, [4] [5] [6] [7] [8] [9] [10] ). This finding might suggest a pre-analytical 291 issue unique to this test or to this study (e.g., mucus on the swab, or the swab itself), but we did 292 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint not see any obvious overrepresentation of either nasal congestion/rhinorrhea or visible 293 blood/mucus on the swabs of those with false positive results. Cross-reactivity with another 294 pathogen in symptomatic patients is another possible explanation. No unusual band 295 morphologies were noted in the 21 false positive results, and all were faint positive bands. We 296 noted occasional "unravelling" of the swab head which might have contributed; because this 297 issue was infrequent, we did not document when it occurred and thus are unable to correlate this 298 event with false positive results. The overall variability we observed in absorption of extraction 299 buffer by the swab head and subsequent elution volume may or may not have contributed to 300 lower specificity. We note that the swab used for this study [SteriPack Sterile Polyester Spun 301 Swab, 3" (Lakeland, Florida)] is the same swab that was used in the CareStart EUA study and 302 will be included in the AN kit going forward. This same swab has been consistently used for 303 RT-PCR testing over the past year at this site, with the same occasional "unravelling" noted at 304 the time of sample collection, indicating that this does not appear to be a lot issue. Logistics of 305 sample collection and testing in high volume at the site did require a window of time between 306 collection and testing (median 31 minutes), but it was not possible to put each swab 307 "immediately" into extraction buffer as stated in the IFU [12] , and our window of one hour 308 between collection and testing was pre-approved by the test manufacturer. Test specificity will 309 need further confirmation in future studies. 310

Our study yielded some important operational findings relevant to test implementation. 312

Inter-operator agreement on positive/negative results was near 100%, confirming that only one 313 person is needed to read each test result. The main challenge to reading the test was 314 distinguishing a faint positive band from a negative result; operators attributed this in part to the 315 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 blue color of the faint positive band resembling a shadow, and recommended use of a strong 316 light source in close proximity to the test device during test reading. 317

The requirement for extraction of the swab in buffer introduced multiple operational challenges. 318

The volume of extraction buffer absorbed by the swab head appeared to be inconsistent, and 319 operators sometimes had difficulty eluting sufficient volume from the head of the swab for 320 testing [by squeezing the sides of the extraction vial as per the IFU; [12] ]. This issue required 321 careful observation and over time became easier for the operators. The occasional unravelling of 322 the swab head in buffer (anecdotally, up to 5/200 tests/day) is described above. Operators noted 323 that it was difficult to peel the foil off the extraction vial while wearing gloves. Additionally, a 324 residual, small drop of buffer on the inner lid of the foil sometimes made gloves slippery with 325 buffer, and operators had difficulty fitting the caps securely on the extraction vials, both of which 326 led to concern about dropping vials during the extraction step. Each skilled laboratorian in the 327 study was able to perform and read ~20 tests per hour; although the test only takes 10' to 328 perform, the short read time window (5') required frequent breaks in test setup and thus 329 decreased throughput. 330

In sum, these operational challenges indicate that dedicated operator training, beyond simply 331 reading the IFU, is warranted for performance of this test to highlight potential failure modes. 332

This recommendation for additional training is consistent with studies that have suggested that 333 specific training in reading positive Ag RDT results may be needed to achieve high specificity 334 [7, 8] , and others that have suggested that the level of training of the operator impacts Ag RDT 335 clinical sensitivity [17] . 336 337 Our study had some limitations. We recognize that the comparator in our study was RT-PCR 338 performed on an AN swab, as opposed to an NP swab, which is still considered the reference 339 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 method by the FDA [18] . This dual AN swab study design was also used for our recent 340

BinaxNOW study [6] . Although AN swabs have had lower sensitivity than NP swabs in some 341 studies, the sensitivity is highly dependent on the sampling technique and assay used [19] . The 342 dry AN swab sampling method used in this study has been shown to have similar sensitivity to 343 paired NP swabs in transport media [13] . We also note that a recent comparison study 344 demonstrated that Ag RDT performance with nasal mid-turbinate swabs was similar to Ag RDT 345 performance with NP swabs [11] . The time interval between sample collection and test initiation 346 in this study is discussed above. Finally, we recognize that our symptomatic pediatric cohort 347 was relatively small and thus the confidence intervals on all performance estimates relatively 348 wide. 349

In summary, the Access Bio CareStart Ag RDT had high sensitivity in individuals with high viral 351 burden (Ct ≤25) and moderate sensitivity in symptomatic individuals overall. Observed 352 specificity was lower than estimates in the manufacturer IFU, slightly lower than some other 353 visually-read Ag RDT products on the market, and unexpectedly lower in symptomatic versus 354 asymptomatic individuals, warranting additional study. Excellent inter-operator agreement was 355 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.07.21253101 doi: medRxiv preprint

COVID-19 Dashboard by the Center for Systems Science and 388

Individual EUAs for Antigen Diagnostic Tests for SARS-393

Evaluation of the accuracy, ease of use and limit 397 of detection of novel, rapid, antigen-detecting point-of-care diagnostics for SARS

Clinical evaluation of the Roche/SD Biosensor rapid 400 antigen test with symptomatic, non-hospitalized patients in a municipal health service 401 drive-through testing site

Performance and Implementation Evaluation of the 403

Testing Site in Massachusetts

Performance characteristics of a rapid SARS-406

CoV-2 antigen detection assay at a public plaza testing site in San Francisco

Field performance and public health response 409 using the BinaxNOW TM Rapid SARS-CoV-2 antigen detection assay during 410 community-based testing

Field evaluation of a rapid antigen test

COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare 413 centres

Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites -416

Head-to-head comparison of SARS-CoV-2

antigen-detecting rapid test with self-collected anterior nasal swab versus professional-420 collected nasopharyngeal swab

Package Insert for the Access Bio CareStart COVID-19 Antigen Test

Clinical Research Sequencing Platform (CRSP), LLC at the Broad Institute of MIT

CRSP SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic 425

Food and Drug Administration

Food and Drug Administration

Package Insert for the Abbott BinaxNOW COVID-19 Ag CARD

Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-436 2 test development and validation cell

Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass 438 community testing

18. Food and Drug Administration. FAQs on Testing for SARS-CoV-2

Performance of Saliva

Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A 446 Systematic Review and Meta-analysis